Prevention of motion sickness with rizatriptan: A double-blind, placebo-controlled pilot study

Medical Science Monitor

Volumn 12, Issue 1, 2006, Pages

  Marcus, Dawn A ^a   Furman, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Migraine; Rizatriptan; Serotonin; Vertigo

Indexed keywords

ERGOTAMINE; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; HYPOTHESIS; MALE; MIGRAINE; MOTION SICKNESS; NORMAL HUMAN; PILOT STUDY; PROVOCATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VESTIBULAR DISORDER; VESTIBULOOCULAR REFLEX;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MOTION SICKNESS; PLACEBOS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 30944445989     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bayazit Y, Yilmaz M, Mumbuc S, Kanlikana M: Assessment of migraine-related cochleovestibular symptoms. Rev Laryngol Otol Rhinol (Bord), 2001;122: 85-88
2. Kayan A, Hood JD: Neuro-otological manifestations of migraine. Brain, 1984; 107: 1123-42
3. Neuhauser H, Leopold M, von Brevern M et al: The interrelations of migraine, vertigo, and migrainous vertigo. Neurology, 2001; 56: 436-41
4. Lee H, Sohn SI, Jung DK et al: Migraine and isolated recurrent vertigo of unknown cause. Neurol Res, 2002; 24: 663-65
5. Marcus DA, Whitney SL, Furman JM: Treatment of migrainous vertigo. Expert Rev Neurotherapeutics, 2003; 3: 307-16
6. Graybiel A, Wood CD, Miller EF, Cramer D: Diagnostic criteria for grading the severity of acute motion sickness. Aerospace Medicine, 1968; 37: 453-55
7. Yates BJ, Miller AD, Lucot JB: Physiological basis and pharmacology of motion sickness: an update. Brain Research Bulletin, 1998; 47: 395-406
8. Drummond PD: Motion sickness and migraine: optokinetic stimulation increases scalp tenderness, pain sensitivity in the fingers and photophobia. Cephalalgia, 2002; 22: 117-24
9. Furman JM, Marcus DA, Balaban C: Migrainous vertigo: development of a pathogenetic model and structural diagnostic interview. Curr Opin Neurol, 2003; 16: 5-13
10. von Brevern M, Zeise D, Neuhauser H et al: Acute migrainous vertigo: clinical and oculographic findings. Brain, 2005; 128: 365-74
11. Nishiike S, Takeda N, Kubo T, Nakamura S: Noradrenergic pathways involved in the development of vertigo and dizziness - a review. Acta Otolaryngol Suppl, 2001; 545: 61-64
12. Takeda N, Morita M, Horii A et al: Neural mechanisms of motion sickness. J Med Invest, 2001; 48: 44-59
13. Halberstadt AL, Balaban CD: Organization of projections from the raphe nuclei to the vestibular nuclei in rats. Neuroscience, 2003; 120: 573-94
14. Jeong HS, Lim YC, Kim TS et al: Excitatory effects of 5-hydroxytryptamine on the medial vestibular nuclear neuron via the 5-HT2 receptor. Neuroreport, 2003; 14: 2001-4
15. Javid FA, Naylor RJ: The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav, 2002; 73: 979-89
16. Burstein R, Collins B, Bajwa Z, Jakubowski M: Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache, 2002; 42: 390-91
17. Neuhauser H, Radtke A, von Brevern M, Lempert T: Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology, 2003; 60: 882-83
18. Yates BJ, Miller AD, Lucot JB: Physiological basis and pharmacology of motion sickness: an update. Brain Research Bulletin, 1998; 47: 395-406
19. Marcus DA, Kapelewski C, Jacob RG et al: Validation of a brief nurse-administered migraine assessment tool. Headache, 2004; 44: 328-32
20. nd edition. Cephalalgia, 2004; 24(Suppl.1): 1-160
21. Marcus DA, Kapelewski C, Rudy TE et al: Diagnosis of migrainous vertigo: validity of a structured interview. Med Sci Monit, 2004; 10(5): CR197-CR201
22. Furman JM, Wuyts F: Clinical Application of Vestibular Laboratory Testing. In: Luxon LM, Martini A, Furman JM, Stephens D, editors. Textbook of audiological medicine. London: Martin Dunitz, 2003: 735-46
23. Wilkins A, Nimmo-Smith I, Tait A et al: Neurological basis for visual discomfort. Brain, 1984; 107: 989-1017
24. Marcus DA, Soso MJ: Migraine and stripe-induced visual discomfort. Arch Neurol, 1989; 46: 1129-32
25. Furman JM, Schor R, Schumann T: Off-Vertical Axis Rotation: A Test of the Otolith-Ocular-Re. ex. Ann Otol Rhinol Laryngol, 1992; 101: 643-50
26. Kennedy RS, Lane NE, Berbaum KS, Lilienthal MG: Simulator sickness questionnaire: an enhanced method for quantifying simulator sickness. Int J Aviat Psychol, 1993; 3: 203-20
27. Wolpe J: The practice of behavior therapy. New York, Pergamon Press, 1982
28. Furman JM, Marcus DA, Balaban CD: Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. Curr Opin Neurol, 2003; 16: 5-13
29. Halberstadt AL, Balaban CD: Organization of projections from the raphe nuclei to the vestibular nuclei in rats. Neuroscience, 2003; 120: 573-94